Cargando…
Drugs commonly associated with weight change: umbrella systematic review and meta-analysis (Protocol)
BACKGROUND: Many drugs and treatments given to patients for various reasons affect their weight. This side effect is of great importance to patients and is also a concern for the treating physician because weight change may lead to the emergence or worsening of other health conditions. OBJECTIVE: Th...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3582551/ https://www.ncbi.nlm.nih.gov/pubmed/23020969 http://dx.doi.org/10.1186/2046-4053-1-44 |
_version_ | 1782260590003093504 |
---|---|
author | Domecq, Juan Pablo Prutsky, Gabriela Wang, Zhen Elraiyah, Tarig Brito, Juan Pablo Mauck, Karen Lababidi, Mohammed H Leppin, Aaron Fidahussein, Salman Prokop, Larry J Montori, Victor M Murad, Mohammad H |
author_facet | Domecq, Juan Pablo Prutsky, Gabriela Wang, Zhen Elraiyah, Tarig Brito, Juan Pablo Mauck, Karen Lababidi, Mohammed H Leppin, Aaron Fidahussein, Salman Prokop, Larry J Montori, Victor M Murad, Mohammad H |
author_sort | Domecq, Juan Pablo |
collection | PubMed |
description | BACKGROUND: Many drugs and treatments given to patients for various reasons affect their weight. This side effect is of great importance to patients and is also a concern for the treating physician because weight change may lead to the emergence or worsening of other health conditions. OBJECTIVE: The aim of this study is to summarize the evidence about commonly prescribed drugs and their association with weight change. METHODS/DESIGN: Umbrella systematic review and meta-analysis of randomized controlled trials. We will use an umbrella approach to identify eligible randomized controlled trials (RCTs). We will search for systematic reviews of RCTs that compare any of the drugs that have been associated with weight gain (obesogenic) or weight loss (leptogenic); these have been summarized by our experts’ panel in a predefined list. Two reviewers will independently determine RCT eligibility. Disagreement will be solved by consensus and arbitrated by a third reviewer. We will extract descriptive, methodological, and efficacy data in duplicate. Our primary continuous outcomes will be weight loss or gain expressed as a mean difference (MD) for weight (kg) or BMI (kg/m(2)). We will calculate the MD considering the mean difference in weight or BMI between baseline and the last available follow-up in both study arms (drugs and placebo). Our primary dichotomous outcome, presented as a relative risk, will compare the ratio of the incidence of weight change in each trial arm. When possible, results will be pooled using classic random-effects meta-analyses and a summary estimate with 95% confidence interval will provided. We will use the I(2) statistic and Cochran’s Q test to assess heterogeneity. The risk of bias will be assessed using the Cochrane risk of bias tool. Publication bias, if appropriate, will be evaluated, as well as overall strength of the evidence. DISCUSSION: This systematic review will offer the opportunity to generate a ranking of commonly prescribed drugs in terms of their effect on weight, allowing guideline developers and patient-physician dyad to choose between available therapies. |
format | Online Article Text |
id | pubmed-3582551 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35825512013-02-27 Drugs commonly associated with weight change: umbrella systematic review and meta-analysis (Protocol) Domecq, Juan Pablo Prutsky, Gabriela Wang, Zhen Elraiyah, Tarig Brito, Juan Pablo Mauck, Karen Lababidi, Mohammed H Leppin, Aaron Fidahussein, Salman Prokop, Larry J Montori, Victor M Murad, Mohammad H Syst Rev Protocol BACKGROUND: Many drugs and treatments given to patients for various reasons affect their weight. This side effect is of great importance to patients and is also a concern for the treating physician because weight change may lead to the emergence or worsening of other health conditions. OBJECTIVE: The aim of this study is to summarize the evidence about commonly prescribed drugs and their association with weight change. METHODS/DESIGN: Umbrella systematic review and meta-analysis of randomized controlled trials. We will use an umbrella approach to identify eligible randomized controlled trials (RCTs). We will search for systematic reviews of RCTs that compare any of the drugs that have been associated with weight gain (obesogenic) or weight loss (leptogenic); these have been summarized by our experts’ panel in a predefined list. Two reviewers will independently determine RCT eligibility. Disagreement will be solved by consensus and arbitrated by a third reviewer. We will extract descriptive, methodological, and efficacy data in duplicate. Our primary continuous outcomes will be weight loss or gain expressed as a mean difference (MD) for weight (kg) or BMI (kg/m(2)). We will calculate the MD considering the mean difference in weight or BMI between baseline and the last available follow-up in both study arms (drugs and placebo). Our primary dichotomous outcome, presented as a relative risk, will compare the ratio of the incidence of weight change in each trial arm. When possible, results will be pooled using classic random-effects meta-analyses and a summary estimate with 95% confidence interval will provided. We will use the I(2) statistic and Cochran’s Q test to assess heterogeneity. The risk of bias will be assessed using the Cochrane risk of bias tool. Publication bias, if appropriate, will be evaluated, as well as overall strength of the evidence. DISCUSSION: This systematic review will offer the opportunity to generate a ranking of commonly prescribed drugs in terms of their effect on weight, allowing guideline developers and patient-physician dyad to choose between available therapies. BioMed Central 2012-09-29 /pmc/articles/PMC3582551/ /pubmed/23020969 http://dx.doi.org/10.1186/2046-4053-1-44 Text en Copyright ©2012 Domecq et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Protocol Domecq, Juan Pablo Prutsky, Gabriela Wang, Zhen Elraiyah, Tarig Brito, Juan Pablo Mauck, Karen Lababidi, Mohammed H Leppin, Aaron Fidahussein, Salman Prokop, Larry J Montori, Victor M Murad, Mohammad H Drugs commonly associated with weight change: umbrella systematic review and meta-analysis (Protocol) |
title | Drugs commonly associated with weight change: umbrella systematic review and meta-analysis (Protocol) |
title_full | Drugs commonly associated with weight change: umbrella systematic review and meta-analysis (Protocol) |
title_fullStr | Drugs commonly associated with weight change: umbrella systematic review and meta-analysis (Protocol) |
title_full_unstemmed | Drugs commonly associated with weight change: umbrella systematic review and meta-analysis (Protocol) |
title_short | Drugs commonly associated with weight change: umbrella systematic review and meta-analysis (Protocol) |
title_sort | drugs commonly associated with weight change: umbrella systematic review and meta-analysis (protocol) |
topic | Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3582551/ https://www.ncbi.nlm.nih.gov/pubmed/23020969 http://dx.doi.org/10.1186/2046-4053-1-44 |
work_keys_str_mv | AT domecqjuanpablo drugscommonlyassociatedwithweightchangeumbrellasystematicreviewandmetaanalysisprotocol AT prutskygabriela drugscommonlyassociatedwithweightchangeumbrellasystematicreviewandmetaanalysisprotocol AT wangzhen drugscommonlyassociatedwithweightchangeumbrellasystematicreviewandmetaanalysisprotocol AT elraiyahtarig drugscommonlyassociatedwithweightchangeumbrellasystematicreviewandmetaanalysisprotocol AT britojuanpablo drugscommonlyassociatedwithweightchangeumbrellasystematicreviewandmetaanalysisprotocol AT mauckkaren drugscommonlyassociatedwithweightchangeumbrellasystematicreviewandmetaanalysisprotocol AT lababidimohammedh drugscommonlyassociatedwithweightchangeumbrellasystematicreviewandmetaanalysisprotocol AT leppinaaron drugscommonlyassociatedwithweightchangeumbrellasystematicreviewandmetaanalysisprotocol AT fidahusseinsalman drugscommonlyassociatedwithweightchangeumbrellasystematicreviewandmetaanalysisprotocol AT prokoplarryj drugscommonlyassociatedwithweightchangeumbrellasystematicreviewandmetaanalysisprotocol AT montorivictorm drugscommonlyassociatedwithweightchangeumbrellasystematicreviewandmetaanalysisprotocol AT muradmohammadh drugscommonlyassociatedwithweightchangeumbrellasystematicreviewandmetaanalysisprotocol |